Browse > Article

A Lipid-derived Endogenous Inducer of COX-2: a Bridge Between Inflammation and Oxidative Stress  

Uchida, Koji (Graduate School of Bioagricultural Sciences, Nagoya University)
Abstract
Several lines of evidence indicate that the oxidative modification of protein and the subsequent accumulation of the modified proteins have been found in cells during aging, oxidative stress, and in various pathological states including premature diseases, muscular dystrophy, rheumatoid arthritis, and atherosclerosis. The important agents that give rise to the modification of a protein may be represented by reactive aldehydic intermediates, such as ketoaldehydes, 2-alkenals and 4-hydroxy-2-alkenals. These reactive aldehydes are considered important mediators of cell damage due to their ability to covalently modify biomolecules, which can disrupt important cellular functions and can cause mutations. Furthermore, the adduction of aldehydes to apolipoprotein B in low-density lipoproteins (LDL) has been strongly implicated in the mechanism by which LDL is converted to an atherogenic form that is taken up by macrophages, leading to the formation of foam cells. During the search for an endogenous inducer of cyclooxygenase-2 (COX-2), an inducible isoform responsible for high levels of prostaglandin production during inflammation and immune responses, 4-hydroxy-2-noennal (HNE), one of the most representative lipid peroxidation product, has been identified as the potential inducer of COX-2. In addition, the following study on the molecular mechanism of the COX-2 induction by HNE has unequivocally established that a serum component, which is eventually identified to be denatured LDL, is essential for COX-2 induction. Here I review current understanding of the mechanisms by which HNE in cooperation with the serum component activates gene expression of COX-2.
Keywords
4-Hydroxy-2-Noennal; Atherosclerosis; Cyclooxygenase-2; Inflammation; Lipid Peroxidation; Low-Density Lipoproteins; Oxidative Stress;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
Times Cited By Web Of Science : 21  (Related Records In Web of Science)
연도 인용수 순위
1 FitzGerald, G.A. (2003). COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2, 879-890   DOI   ScienceOn
2 Ishii, T., Itoh, K., Ruiz, E., Leake, D.S., Unoki, H., Yamamoto, M., and Mann, G.E. (2004). Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ. Res. 94, 609-616   DOI   ScienceOn
3 Kumagai, T., Kawamoto, Y., Nakamura, Y., Hatayama, I., Satoh, K., Osawa, T., and Uchida, K. (2000). 4-Hydroxy-2-nonenal, the end product of lipid peroxidation, is a specific inducer of cyclooxygenase-2 gene expression. Biochem. Biophys. Res. Commun. 273, 437-771   DOI   ScienceOn
4 Nagy, L., Tontonoz, P., Alvarez, J.G., Chen, H., and Evans, R.M. (1998). Oxidized LDL regulates macrophage gene expression through ligand activation of PPARg. Cell 93, 229-240   DOI   ScienceOn
5 Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., and Witztum, J.L. (1989). Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320, 915-924   DOI   ScienceOn
6 Suc, I., Meilhac, O., Lajoie-Mazenc, I., Vandaele, J., Jurgens, G., Salvayre, R., and Negre-Salvayre, A. (1998). Activation of EGF receptor by oxidized LDL. FASEB J. 12, 665-671   DOI
7 Ziouzenkova, O., Asatryan, L., Akmal, M., Tetta, C., Wratten, M.-L., Heinecke, J., and Sevanian, A. (1999). Cross-linking between low density lipoprotein apoB and hemoglobin mediates conversion to electronegative LDL- during the ex-vivo blood circulation. J. Biol. Chem. 274, 18916-18924   DOI
8 Kanayama, M., Yamaguchi, S., Shibata, T., Shibata, N., Kobayashi, M., Nagai, R., Arai, H., Takahashi, K., and Uchida, K. (2007). Identification of a serum component that regulates cyclooxygenase-2 gene expression in cooperation with 4- hydroxy-2-nonenal. J. Biol. Chem. 282, 24166-24174   DOI   ScienceOn
9 Podrez, E.A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton, P.J., Shan, L., Gugiu, B., Fox, P.L., et al. (2002). Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 277, 38503-38516   DOI   ScienceOn
10 Uchida, K. (2003). 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 42, 318-343   DOI   ScienceOn
11 Quinn, M.T., Parthasarathy, S., Fong, L.G., and Steinberg, D. (1987). Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA 84, 2995-2998
12 Kumagai, T., Nakamura, Y., Osawa, T., and Uchida, K. (2002). Role of p38 mitogen-activated protein kinase in the 4- hydroxy-2-nonenal-induced cyclooxygenase-2 expression. Arch. Biochem. Biophys. 397, 240-245   DOI   ScienceOn
13 Sevanian, A., Hwang, J., Hodis, H.N., Cazzolato, G., Avogaro, P., and Bittolo-Bon, G. (1996). Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler. Thromb. 16, 784-793   DOI   ScienceOn
14 Gimbrone, M.A. Jr., Topper, J.N., Nagel, T., Anderson, K.R., and Garcia-Cardena, G. (2000). Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann. N.Y. Acad. Sci. 902, 230-239   DOI
15 Huang, D., Jang, B.C., Yu, G., and Boudreau, M. (1997). Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: mediation through both mitogen-activated protein kinase and NF-${\kappa}B$ signaling pathways in macrophages. Biochem. Pharmacol. 54, 87-96   DOI   ScienceOn
16 Sevanian, A., Asatryan, L., and Ziouzenkova, O. (1999). Low density lipoprotein (LDL) modification: basic concepts and relationship to atherosclerosis. Blood Purif. 17, 66-78   DOI   ScienceOn
17 Glass, C.K., and Witztum, J.L. (2001). Atherosclerosis. The road ahead. Cell 104, 503-516   DOI   ScienceOn
18 Steinberg, D. (1995). Role of oxidized LDL and antioxidants in atherosclerosis. Adv. Exp. Med. Biol. 369, 39-48
19 Koki, A., Khan, N.K., Woerner, B.M., Dannenberg, A.J., Olson, L., Seibert, K., Edwards, D., Hardy, M., Isakson, P., and Masferrer, J.L. (2002). Cyclooxygenase-2 in human pathological disease. Adv. Exp. Med. Biol. 507, 177-184
20 Reddy, S.T., Wadleigh D.J., and Herschman, H.R. (2000). Transcriptional regulation of the cyclooxygenase-2 gene in activated mast cells. J. Biol. Chem. 275, 3107-3113   DOI   ScienceOn
21 Smith, W.L., and Langenbach, R. (2001). Why there are two cyclooxygenase isozymes. J. Clin. Invest. 107, 1491-1495   DOI   ScienceOn
22 Kumagai, T., Matsukawa, N., Kaneko, Y., Kusumi, Y., Mitsumata, M., and Uchida, K. (2004). A lipid peroxidationderived inflammatory mediator: Identification of 4-hydroxy- 2-nonenal as a potential inducer of cyclooxygenase-2 in macrophages. J. Biol. Chem. 279, 48389-48396   DOI   ScienceOn
23 FitzGerald, G.A., Austin, S., Egan, K., Cheng, Y., and Pratico, D. (2000). Cyclo-oxygenase products and atherothrombosis. Ann. Med. 32, 21-26
24 Sevanian, A., Bittolo-Bon, G., Cazzolato, G., Hodis, H., Hwang, J., Zamburlini, A., Maiorino, M., and Ursini, F. (1997). LDLis a lipid hydroperoxide-enriched circulating lipoprotein. J. Lipid Res. 38, 419-428